{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-11-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "letter_date": "05/15/2025",
      "approver_title": null,
      "file_name": "CRL_NDA215244_20250515.pdf",
      "letter_year": "2025",
      "approval_status": "Unapproved",
      "approver_name": "Center for Drug Evaluation and Research",
      "approver_center": [],
      "company_rep": "Jim Carr",
      "company_address": "123 Highland Avenue, Suite 201\nNeedham, MA 02494",
      "company_name": "Stealth BioTherapeutics Inc.",
      "text": "i Lk YN U.S. FOOD & DRUG\n\nADMINISTRATION\n\nNDA 215244\nCOMPLETE RESPONSE\n\nStealth BioTherapeutics Inc.\nAttention: Jim Carr\n\nChief Clinical Development Officer\n123 Highland Avenue, Suite 201\nNeedham, MA 02494\n\nDear Jim Carr:\n\nPlease refer to your new drug application (NDA) oe\n\nfor elamipretide injection.\nWe acknowledge receipt of your major amendments dated oe\n, which extended the goal date by three months.\n\nWe have completed our review of this application, as amended, and have determined\nthat we cannot approve this application in its present form. We have described our\nreasons for this action below and our recommendations to address these issues.\n\nWe recognize that Barth syndrome (BTHS) is a rare, serious, disease with significant\ndisability and premature mortality and that there is high unmet need with no approved\ntherapies. We extensively evaluated whether the evidence for the endpoints that directly\nassessed clinical benefit (i.e., how patients feel, function, or survive) in your studies\ncould establish the effectiveness of elamipretide for traditional approval. We also\nextensively assessed your proposal to use left ventricular stroke volume (LVSV), the\nmonolysocardiolipin (MLCL):tetralinoleoy! cardiolipin (CL) ratio, or acylcarnitines as\nsurrogate endpoints reasonably likely to predict clinical benefit for accelerated approval.\nFor the reasons described below, we are unable to conclude that these approaches\nestablish the effectiveness of elamipretide for traditional or accelerated approval, even\nwhen applying regulatory flexibility for this rare, serious disease.\n\nHowever, one of the endpoints in SPIBA-201, Part 2 — muscle strength of the knee\nextensors assessed using handheld dynamometry — could be reasonable as an\nintermediate clinical endpoint for accelerated approval. If you would like to pursue this\napproach, we discuss the path forward towards the end of this letter.\n\nIn addition, we identified deficiencies at the drug product manufacturing facility that will\n\nneed to be resolved before this application can be approved. See the “Facility\nInspections” section for further details.\n\nReference ID: 5592085\n\nNDA 215244\nPage 2\n\nDEFICIENCIES\nTraditional Approval\n\nThe effectiveness of elamipretide has not been established for traditional approval for\nthe following reasons:\n\nSPIBA-201, Part 1:\n\nSPIBA-201, Part 1, the only randomized, placebo-controlled, study of elamipretide in\npatients with BTHS, did not show superiority of elamipretide to placebo on the primary\nendpoint family of distance walked on 6-minute walk test (6MWT) (p=0.97) and total\nfatigue score (TFS) on the Barth syndrome symptom assessment (p=0.89) at the end of\nthe 12-week treatment period. While there was no alpha remaining to test secondary\nendpoints, it is notable that none of the secondary endpoints were even nominally\nstatistically significant.\n\nSPIBA-201, Part 2:\n\nSPIBA-201, Part 2 was an open-label, single-arm, extension of SPIBA-201, Part 1 that\nevaluated longitudinal trends with elamipretide treatment for several secondary\nendpoints that directly assessed clinical benefit such as distance walked on 6MWT,\nTFS, 5-times sit-stand test, and patient and clinician reported outcomes. We were\nunable to conclude that there is evidence of a meaningful treatment effect with\nelamipretide based on these findings. Our predominant concerns were related to bias\ninvolving endpoints that are effort-dependent and/or could be impacted by subjects\nknowing they were receiving elamipretide. We determined that this bias could not be\novercome considering the effect sizes on these endpoints and the extent to which there\nwas improvement on these endpoints while the subjects received placebo during\nSPIBA-201, Part 1.\n\nFor example, with respect to 6MWT, there were notable increases in distance walked\nwith placebo in SPIBA-201, Part 1. In addition, mean increases from screening in\ndistances walked on 6MWT with elamipretide were generally only 8-22 meters at the\nvarious timepoints during SPIBA-201, Part 2 for all but two subjects, which is well within\nwhat could be expected based on effort and not large enough to overcome the concern\nof effort dependence. For the remaining two subjects, the longer distance walked on\n6MWT was confounded by considerable growth during the treatment period for one of\nthe subjects, leaving only a single subject who had a larger increase in distance walked\non 6MWT, and in whom it is not possible to reliably conclude that the larger increase in\ndistance walked is due to elamipretide.\n\nWith regard to TFS, the reductions in SPIBA-201, Part 2 were generally similar to the\nextent of reductions seen in both the elamipretide and placebo groups during Part 1. For\n\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\n\nReference ID: 5592085\n\nNDA 215244\nPage 3\n\nfive times sit-to-stand test, none of the changes from baseline during Part 2 were\nnominally statistically significant. The changes on SWAY Balance Scores and the small\nchanges on the Patient and Clinician Global Impression Scales were also difficult to\ninterpret in this open-label, single-arm study.\n\nSPIBA-001:\n\nSPIBA-001 was an externally controlled study that compared the elamipretide-treated\nsubjects who participated in SPIBA-201, Part 2 to a natural history cohort, assessing\nsome of the same clinical endpoints as SPIBA-201 either individually or together within\na multidomain responder index. We were unable to conclude that there is evidence of a\nmeaningful treatment effect with elamipretide based on these findings. Our predominant\nconcern was related to bias involving endpoints that were effort-dependent and could be\nimpacted by subjects knowing whether they were receiving elamipretide. This concern\nidentified for these endpoints for the elamipretide-treated subjects in SPIBA-201, Part 2\ncould not be overcome by comparing these subjects to an external control of patients\nwho knew they were not receiving elamipretide and, therefore, would have no\nexpectation that they would improve.\n\nWe also identified several other significant limitations of SPIBA-001 that further affected\ninterpretability of the findings. These other limitations include concerns with selection\nbias and comparability of the control to the treated arm, issues with the propensity score\nmethodology (e.g., limited number of measured covariates, making the statistical\ninference likely subject to bias from unmeasured confounding; also the sample size was\ninsufficient for the propensity score method), 100% interpolation of efficacy data where\ninterpolated values can differ dramatically from observed values around the timepoints\nof interest, and uncertain reliability of the control data because of a lack of audit trail\nfrom the initial recording in a Microsoft excel spreadsheet to the REDCap Database\nsystem.\n\nAccelerated Approval\n\nIn your cover letter with your NDA resubmission, you proposed that if the findings on the\nclinical endpoints were not sufficient for traditional approval that FDA consider\naccelerated approval based on surrogate endpoints of LVSV, MLCL:CL ratio, and/or\nacylcarnitines, and/or an intermediate clinical endpoint such as BMWT. FDA has\nconsistently used 6MWT as an endpoint for full approval (it is a direct measure of\nclinical benefit), not as an intermediate clinical endpoint for accelerated approval.\nFurthermore, as discussed above, we are unable to conclude there is a meaningful\ntreatment effect of elamipretide on distance walked on 6MWT.\n\nWhile your proposed endpoints of LVSV, MLCL:CL ratio, and/or acylcarnitines are not\neffort dependent or impacted by knowledge of treatment assignment, we identified the\nfollowing major limitations, precluding their use for accelerated approval for\nelamipretide.\n\nU.S. Food and Drug Administration\n\nSilver Spring, MD 20993\n\nwww.fda.gov\n\nReference ID: 5592085\n\nNDA 215244\nPage 4\n\nLVSV:\n\nYou evaluated LVSV as an exploratory endpoint in SPIBA-201, Part 1 and Part 2. We\nnote that all subjects had normal left ventricular (LV) function at the baseline (Visit 1,\nPredose) echocardiographic assessment. Small increases in mean 3D LVSV indexed\n(LVSVi) to baseline body surface area (BSA) were observed, but mean LVSVi generally\nremained within the normal range at various timepoints. The clinical relevance of these\nchanges in LVSV that remained within the normal range is unclear.\n\nFurthermore, changes in LVSV are observed with increasing age in normal individuals.\nFor example, during childhood and adolescence, LVSV generally increases, but in\nadulthood, LVSV decreases with age. Therefore, the impact of increasing age over the\nduration of SPIBA-201, Part 2 on these findings is uncertain. In addition, the increase in\nLV end diastolic volume indexed (LVEDVi) to BSA appears to be the predominant\nreason for the observed increase in LVSVi, and an increase in LVEDVi can be an\nadverse finding (e.g., when patients progress from normal LV to dilated\ncardiomyopathy).\n\nGiven little evidence of cardiomyopathy at baseline, the variable course of the disease\nbetween subjects, the lack of a control arm, expected age-related changes in LVSV,\nand lack of information about the hemodynamic condition when LVSV was estimated\n(LVSV is impacted by both cardiac and extracardiac factors such as circulating blood\nvolume, cardiac function and vascular tone), we are unable to interpret the observed\nincrease in LVSVi in Part 2 as a treatment effect of elamipretide.\n\nMLCL:CL Ratio:\n\nElamipretide did not improve the MLCL:CL ratio in an animal model of BTHS. There\nwere also no significant differences in the MLCL:CL ratio between elamipretide and\nplacebo-treated subjects in SPIBA-201, Part 1. While a decline in the MLCL:CL ratio\nfrom SPIBA-201, Part 1 predose baseline to Part 2 was seen for 7 of 8 subjects, some\nof the largest reductions in the ratio occurred while subjects were receiving placebo in\nPart 1, with the ratios remaining relatively flat throughout Part 2. Therefore, we are\nunable to conclude that there is a treatment effect of elamipretide on the MLCL:CL ratio.\n\nAcylcarnitines:\n\nYou referenced the Oates et al. 2020 publication that reported a nominally significant\ndecrease in some, but not all plasma and urine acylcarnitines with elamipretide\ncompared to placebo in SPIBA-201, Part 1. The utility of these exploratory results\n(which the article attributes to improved mitochondrial metabolism), is unclear given that\nelamipretide was not superior to placebo on any of the primary or secondary endpoints\nin Part 1. These exploratory acylcarnitine biomarker results are not sufficient for use as\na surrogate endpoint for accelerated approval.\n\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\n\nReference ID: 5592085\n\nNDA 215244\nPage 5\n\nPATH FORWARD\n\nFDA is considering the endpoint on muscle strength of the knee extensors assessed\nusing handheld dynamometry in SPIBA-201, Part 2, as a potential intermediate clinical\nendpoint for accelerated approval of elamipretide, if it is reasonably likely to predict a\nclinical benefit in BTHS. This endpoint could not be considered for traditional approval\nbecause it assessed only a single muscle group and was not accompanied by clinical\nbenefit (e.g., an improvement in how patients function). We encourage you to request\nan End-of-Review meeting to discuss this potential approach. In the briefing document\nfor this meeting, provide FDA with information on what clinical benefit this endpoint\nwould be reasonably likely to predict and include your proposed design of a\nconfirmatory postmarketing clinical trial that would be able to verify whether elamipretide\nhas this predicted clinical benefit.\n\nFACILITY INSPECTIONS\nFollowing a CGMP inspection of om\n\nisted in this application, FDA conveyed deficiencies to the representative\nof the facility. The facility should provide satisfactory responses to these deficiencies to\nthe FDA office indicated on the FDA 483 prior to submission of your complete response.\nThe facility's satisfactory responses are dependent on FDA’s determination that the\nfacility has come into compliance with CGMP and may require re-inspection of the\nfacility. The deficiencies identified during the inspection may not be specific to your\napplication. Therefore, you should coordinate with the facility for timely resolution. Your\ncomplete response should include the date(s) of the facility's response(s) to the FDA\nForm 483. Please refer to Compliance Program CP 7356.002 for guidance on post\ninspection activities. Following resolution of the CGMP inspection, FDA may need to\nconduct a preapproval inspection (PAI) of the facility. Satisfactory outcomes of both the\nPAI and the CGMP surveillance inspections will be needed prior to an approval of the\napplication.\n\nPRESCRIBING INFORMATION\n\nWe reserve comment on the proposed labeling until the application is otherwise\nadequate. We encourage you to review the labeling review resources on the\nPrescription Drug Labeling Resources! and Pregnancy and Lactation Labeling Final\nRule? websites, including regulations and related guidance documents and the Selected\nRequirements for Prescribing Information (SRPI) - a checklist of important format items\nfrom labeling regulations and guidances.\n\n1 https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources\n\n2 https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-\nfinal-rule\n\nU.S. Food and Drug Administration\n\nSilver Spring, MD 20993\n\nwww.fda.gov\n\nReference ID: 5592085\n\nNDA 215244\nPage 6\n\nCARTON AND CONTAINER LABELING\n\nWe acknowledge receipt of your revised carton and container labeling submitted on\n. We reserve further comment on the proposed labeling until the\napplication is otherwise adequate.\n\nPROPRIETARY NAME\n\nPlease refer to correspondence dated, oe , which addresses the proposed\nproprietary name,! ™ . This name was found conditionally acceptable pending\napproval of the application in the current review cycle. Please resubmit the proposed\nproprietary name when you respond to all of the application deficiencies that have been\nidentified in this letter.\n\nSAFETY UPDATE\n\nWhen you respond to the above deficiencies, include a safety update as described at\n21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical\nand clinical studies/trials of the drug under consideration regardless of indication,\ndosage form, or dose level.\n\n(1) Describe in detail any significant changes or findings in the safety profile.\n\n(2) When assembling the sections describing discontinuations due to adverse\nevents, serious adverse events, and common adverse events, incorporate new\nsafety data as follows:\n\ne Present new safety data from the studies/clinical trials for the proposed\nindication using the same format as in the original submission.\n\ne Present tabulations of the new safety data combined with the original\napplication data.\n\ne Include tables that compare frequencies of adverse events in the original\napplication with the retabulated frequencies described in the bullet above.\n\ne For indications other than the proposed indication, provide separate tables for\nthe frequencies of adverse events occurring in Clinical trials.\n\n(3) Present a retabulation of the reasons for premature trial discontinuation by\nincorporating the dropouts from the newly completed trials. Describe any new\ntrends or patterns identified.\n\n(4) Provide case report forms and narrative summaries for each subject who died\nduring a Clinical trial or who did not complete a trial because of an adverse event.\nIn addition, provide narrative summaries for serious adverse events.\nU.S. Food and Drug Administration\n\nSilver Spring, MD 20993\nwww.fda.gov\n\nReference ID: 5592085\n\nNDA 215244\nPage 7\n\n(5) Describe any information that suggests a substantial change in the incidence of\ncommon, but less serious, adverse events between the new data and the original\napplication data.\n\n(6) Provide updated exposure information for the clinical studies/trials (e.g., number\nof subjects, person time).\n\n(7) Provide a summary of worldwide experience on the safety of this drug. Include\nan updated estimate of use for drug marketed in other countries.\n\n(8) Provide English translations of current approved foreign labeling not previously\nsubmitted.\n\nPOSTMARKETING REQUIREMENTS UNDER 505(0)(3)\n\nSection 505(0)(3) of the FDCA authorizes FDA to require holders of approved drug and\nbiological product applications to conduct postmarketing studies and clinical trials for\ncertain purposes, if FDA makes certain findings required by the statute.\n\nBased on a weight of evidence evaluation, the human carcinogenic potential of\nelamipretide is uncertain. A 26-week carcinogenicity study in TgRasH2 mice and 2-year\nrat carcinogenicity study are warranted to complete the safety assessment.\n\nIn addition, based on the results of an in vitro drug interaction study, there is a risk for in\nvivo interaction between elamipretide and substrates of MATE1. A pharmacokinetic\n(PK) study is warranted to evaluate the potential for in vivo interaction with substrates of\nMATE1.\n\nFDA has determined that if NDA 215244 is approved, an analysis of spontaneous\npostmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not\nbe sufficient to assess these serious risks of carcinogenicity and drug-drug interactions.\n\nFurthermore, the active postmarket risk identification and analysis system as available\nunder section 505(k)(3) of the FDCA will not be sufficient to assess these serious risks.\n\nTherefore, based on appropriate scientific data, FDA has determined that, if NDA\n215244 is approved, you will be required to conduct the following postmarketing studies:\n\n1. A long-term (2-year) GLP carcinogenicity study of elamipretide administered\nby subcutaneous injection in rats.\n\n2. A 26-week GLP carcinogenicity study of elamipretide administered by\nsubcutaneous injection in TgRasH2 mice.\n\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\n\nReference ID: 5592085\n\nNDA 215244\nPage 8\n\n3. Aclinical PK study to evaluate the effect of repeat doses of elamipretide on\nthe single dose PK of metformin (a sensitive MATE1 substrate)\n\nAny additional specific details of these required postmarketing studies, including a\ntimetable and annual reporting requirements, will be described more fully in the\napproval letter for this application, if it is approved.\n\nIf you complete these studies prior to re-submitting your application, include the final\nreport and relevant data sets in your complete response submission to facilitate review\nof the information.\n\nADDITIONAL COMMENTS\n\nWe have the following comments and recommendations that are not approvability\nissues:\n\nWe have received several expanded access requests for elamipretide for infants with\nBTHS. We encourage you to systematically study the effectiveness and safety of\nelamipretide in this patient population. It will not be possible to extrapolate efficacy\nfindings from the more stable subjects 12 years and older evaluated in your existing\nstudies to those who present with life-threatening heart failure soon after birth. It will\nalso be important to systematically collect safety information in this younger patient\npopulation. We are committed to working with you on the design of a feasible and\ninterpretable study.\n\nOTHER\n\nWithin one year after the date of this letter, you are required to resubmit or take other\nactions available under 21 CFR 314.110. If you do not take one of these actions, we\nmay consider your lack of response a request to withdraw the application under\n\n21 CFR 314.65. You may also request an extension of time in which to resubmit the\napplication.\n\nA resubmission must fully address all the deficiencies listed in this letter and should be\nclearly marked with \"RESUBMISSION\" in large font, bolded type at the beginning of the\ncover letter of the submission. The cover letter should clearly state that you consider\nthis resubmission a complete response to the deficiencies outlined in this letter. A partial\nresponse to this letter will not be processed as a resubmission and will not start a new\nreview cycle.\n\nYou may request a meeting or teleconference with us to discuss what steps you need to\ntake before the application may be approved. If you wish to have such a meeting,\nsubmit your meeting request as described in the draft guidance for industry Formal\nMeetings Between the FDA and Sponsors or Applicants of PDUFA Products.\n\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\n\nReference ID: 5592085\n\nNDA 215244\nPage 9\n\nThe product may not be legally marketed until you have been notified in writing that this\napplication is approved.\n\nIf you have any questions, contact\n\nSincerely,\n\n{See appended electronic signature page}\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\n\nReference ID: 5592085\n\nSignature Page 1 of 1\n\nThis is a representation of an electronic record that was signed\nelectronically. Following this are manifestations of any and all\nelectronic signatures for this electronic record.\n\n(b) (4)\n\n05/15/2025 04:25:09 PM\n\nReference ID: 5592085\n",
      "application_number": [
        "NDA 215244"
      ],
      "letter_type": "COMPLETE RESPONSE"
    }
  ]
}